http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Repare Therapeutics Inc. (RPTX) Achieves $40M Roche Clinical Milestone Payment
-
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
-
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
-
Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
-
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
-
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
-
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
-
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
-
Repare Therapeutics (RPTX) Reports Positive Initial Data from Phase 1 MYTHIC Clinical Trial
-
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
-
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
-
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
-
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
-
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
-
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
-
Repare Therapeutics (RPTX) Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors
-
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
-
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Repare Therapeutics Inc. (RPTX) Announces $1.5M Payment from Ono Pharmaceuticals
-
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
-
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
-
Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021
-
Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors
-
Cathie Wood's ARK Adds ~1.7M Shares of Twitter (TWTR), Sells Apple (AAPL), Alibaba (BABA)
-
Cathie Wood's ARK Adds $170M in Tesla (TSLA) Stock on Tuesday's Drop, Among Other Trades
-
Cathie Wood's ARK Bought Buys ~$200M More Tesla (TSLA) Monday on Sell-Off